Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982851 | 1.00 | KMT2A (0.56) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL29450606 | 0.88 | KMT2A (0.65) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL16982846 | 0.87 | MAPT (0.56) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL29450637 | 0.80 | POLB (0.64) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL29450610 | 0.80 | KMT2A (0.67) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL18354581 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2RAB9ANPC1KDM4EPOLB | |
| SCHEMBL29450622 | 0.76 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL16982845 | 0.75 | NPC1 (0.48) | RAB9ANPC1KDRKDM4EPOLB | |
| SCHEMBL6439308 | 0.75 | KMT2A (1.00) | KMT2ASMN1; SMN2MEN1HTTRAB9A | |
| SCHEMBL13314757 | 0.74 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | KMT2A 1356/4885SMN1; SMN2 3268/4885MEN1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.